当前位置: 首页 >> 检索结果
61. Oral Nirmatrelvir-Ritonavir as Postexposure Prophylaxis for Covid-19.
作者: Jennifer Hammond.;Carla Yunis.;Robert J Fountaine.;Gerald Luscan.;Aimee M Burr.;Wuyan Zhang.;Wayne Wisemandle.;Holly Soares.;Mary Lynn Baniecki.;Victoria M Hendrick.;Veselin Kalfov.;Rienk Pypstra.;James M Rusnak.
来源: N Engl J Med. 2024年391卷3期224-234页
Clinical trials of treatments for coronavirus disease 2019 (Covid-19) have not shown a significant benefit of postexposure prophylaxis.
62. Postacute Sequelae of SARS-CoV-2 Infection in the Pre-Delta, Delta, and Omicron Eras.
Postacute sequelae of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (PASC) can affect many organ systems. However, temporal changes during the coronavirus disease 2019 (Covid-19) pandemic, including the evolution of SARS-CoV-2, may have affected the risk and burden of PASC. Whether the risk and burden of PASC have changed over the course of the pandemic is unclear.
64. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity.
作者: Atul Malhotra.;Ronald R Grunstein.;Ingo Fietze.;Terri E Weaver.;Susan Redline.;Ali Azarbarzin.;Scott A Sands.;Richard J Schwab.;Julia P Dunn.;Sujatro Chakladar.;Mathijs C Bunck.;Josef Bednarik.; .
来源: N Engl J Med. 2024年391卷13期1193-1205页
Obstructive sleep apnea is characterized by disordered breathing during sleep and is associated with major cardiovascular complications; excess adiposity is an etiologic risk factor. Tirzepatide may be a potential treatment.
65. Combination Targeted Therapy in Relapsed Diffuse Large B-Cell Lymphoma.
作者: Christopher Melani.;Rahul Lakhotia.;Stefania Pittaluga.;James D Phelan.;Da Wei Huang.;George Wright.;Jillian Simard.;Jagan Muppidi.;Craig J Thomas.;Michele Ceribelli.;Frances A Tosto.;Yandan Yang.;Weihong Xu.;Theresa Davies-Hill.;Svetlana D Pack.;Cody J Peer.;Oluwatobi Arisa.;Esther Mena.;Liza Lindenberg.;Ethan Bergvall.;Craig A Portell.;Rafic J Farah.;Seung Tae Lee.;Amynah Pradhan.;Candis Morrison.;Atekelt Tadese.;Anna Marie Juanitez.;Crystal Lu.;Allison Jacob.;Heidi Simmons.;William D Figg.;Seth M Steinberg.;Elaine S Jaffe.;Mark Roschewski.;Louis M Staudt.;Wyndham H Wilson.
来源: N Engl J Med. 2024年390卷23期2143-2155页
The identification of oncogenic mutations in diffuse large B-cell lymphoma (DLBCL) has led to the development of drugs that target essential survival pathways, but whether targeting multiple survival pathways may be curative in DLBCL is unknown.
66. Inactivation of Avian Influenza A(H5N1) Virus in Raw Milk at 63°C and 72°C.
作者: Franziska Kaiser.;Dylan H Morris.;Arthur Wickenhagen.;Reshma Mukesh.;Shane Gallogly.;Kwe Claude Yinda.;Emmie de Wit.;James O Lloyd-Smith.;Vincent J Munster.
来源: N Engl J Med. 2024年391卷1期90-92页 67. Noninvasive Ventilation for Preoxygenation during Emergency Intubation.
作者: Kevin W Gibbs.;Matthew W Semler.;Brian E Driver.;Kevin P Seitz.;Susan B Stempek.;Caleb Taylor.;Daniel Resnick-Ault.;Heath D White.;Sheetal Gandotra.;Kevin C Doerschug.;Amira Mohamed.;Matthew E Prekker.;Akram Khan.;John P Gaillard.;Luke Andrea.;Neil R Aggarwal.;Jason C Brainard.;LuAnn H Barnett.;Stephen J Halliday.;Veronika Blinder.;Alon Dagan.;Micah R Whitson.;Steven G Schauer.;James E Walker.;Andrew B Barker.;Jessica A Palakshappa.;Amelia Muhs.;Joanne M Wozniak.;Patrick J Kramer.;Cori Withers.;Shekhar A Ghamande.;Derek W Russell.;Andrei Schwartz.;Ari Moskowitz.;Sydney J Hansen.;Gopal Allada.;Jordan K Goranson.;Daniel G Fein.;Peter D Sottile.;Nicholas Kelly.;Shannon M Alwood.;Micah T Long.;Rishi Malhotra.;Nathan I Shapiro.;David B Page.;Brit J Long.;Christopher B Thomas.;Stacy A Trent.;David R Janz.;Todd W Rice.;Wesley H Self.;Vikhyat S Bebarta.;Bradley D Lloyd.;Jillian Rhoads.;Kelsey Womack.;Brant Imhoff.;Adit A Ginde.;Jonathan D Casey.; .
来源: N Engl J Med. 2024年390卷23期2165-2177页
Among critically ill adults undergoing tracheal intubation, hypoxemia increases the risk of cardiac arrest and death. The effect of preoxygenation with noninvasive ventilation, as compared with preoxygenation with an oxygen mask, on the incidence of hypoxemia during tracheal intubation is uncertain.
68. Near-Universal Resistance to Macrolides of Treponema pallidum in North America.
作者: Nicole A P Lieberman.;Tara B Reid.;Chase A Cannon.;B Ethan Nunley.;Anna Berzkalns.;Stephanie E Cohen.;Lori M Newman.;Sol Aldrete.;Linda H Xu.;Clinton P Thornlund.;Kevin Pettus.;Stephanie Lundy.;Michael Kron.;Olusegun O Soge.;Kimberly Workowski.;Charlotte Perlowski.;Edward W Hook.;Jodie A Dionne.;Matthew R Golden.;Joshua A Lieberman.;Min-Kuang Lee.;Muhammad Morshed.;Prenilla Naidu.;Weiping Cao.;Allan Pillay.;Lorenzo Giacani.;Alexander L Greninger.
来源: N Engl J Med. 2024年390卷22期2127-2128页 69. Risk of Second Tumors and T-Cell Lymphoma after CAR T-Cell Therapy.
作者: Mark P Hamilton.;Takeshi Sugio.;Troy Noordenbos.;Shuyu Shi.;Philip L Bulterys.;Chih Long Liu.;Xiaoman Kang.;Mari N Olsen.;Zinaida Good.;Saurabh Dahiya.;Matthew J Frank.;Bita Sahaf.;Crystal L Mackall.;Dita Gratzinger.;Maximilian Diehn.;Ash A Alizadeh.;David B Miklos.
来源: N Engl J Med. 2024年390卷22期2047-2060页
The risk of second tumors after chimeric antigen receptor (CAR) T-cell therapy, especially the risk of T-cell neoplasms related to viral vector integration, is an emerging concern.
71. Genome Sequencing for Diagnosing Rare Diseases.
作者: Monica H Wojcik.;Gabrielle Lemire.;Eva Berger.;Maha S Zaki.;Mariel Wissmann.;Wathone Win.;Susan M White.;Ben Weisburd.;Dagmar Wieczorek.;Leigh B Waddell.;Jeffrey M Verboon.;Grace E VanNoy.;Ana Töpf.;Tiong Yang Tan.;Steffen Syrbe.;Vincent Strehlow.;Volker Straub.;Sarah L Stenton.;Hana Snow.;Moriel Singer-Berk.;Josh Silver.;Shirlee Shril.;Eleanor G Seaby.;Ronen Schneider.;Vijay G Sankaran.;Alba Sanchis-Juan.;Kathryn A Russell.;Karit Reinson.;Gianina Ravenscroft.;Maximilian Radtke.;Denny Popp.;Tilman Polster.;Konrad Platzer.;Eric A Pierce.;Emily M Place.;Sander Pajusalu.;Lynn Pais.;Katrin Õunap.;Ikeoluwa Osei-Owusu.;Henry Opperman.;Volkan Okur.;Kaisa Teele Oja.;Melanie O'Leary.;Emily O'Heir.;Chantal F Morel.;Andreas Merkenschlager.;Rhett G Marchant.;Brian E Mangilog.;Jill A Madden.;Daniel MacArthur.;Alysia Lovgren.;Jordan P Lerner-Ellis.;Jasmine Lin.;Nigel Laing.;Friedhelm Hildebrandt.;Julia Hentschel.;Emily Groopman.;Julia Goodrich.;Joseph G Gleeson.;Roula Ghaoui.;Casie A Genetti.;Janina Gburek-Augustat.;Hanna T Gazda.;Vijay S Ganesh.;Mythily Ganapathi.;Lyndon Gallacher.;Jack M Fu.;Emily Evangelista.;Eleina England.;Sandra Donkervoort.;Stephanie DiTroia.;Sandra T Cooper.;Wendy K Chung.;John Christodoulou.;Katherine R Chao.;Liam D Cato.;Kinga M Bujakowska.;Samantha J Bryen.;Harrison Brand.;Carsten G Bönnemann.;Alan H Beggs.;Samantha M Baxter.;Tobias Bartolomaeus.;Pankaj B Agrawal.;Michael Talkowski.;Christina Austin-Tse.;Rami Abou Jamra.;Heidi L Rehm.;Anne O'Donnell-Luria.
来源: N Engl J Med. 2024年390卷21期1985-1997页
Genetic variants that cause rare disorders may remain elusive even after expansive testing, such as exome sequencing. The diagnostic yield of genome sequencing, particularly after a negative evaluation, remains poorly defined.
72. Phase 3 Trial of Crinecerfont in Adult Congenital Adrenal Hyperplasia.
作者: Richard J Auchus.;Oksana Hamidi.;Rosario Pivonello.;Irina Bancos.;Gianni Russo.;Selma F Witchel.;Andrea M Isidori.;Patrice Rodien.;Umasuthan Srirangalingam.;Florian W Kiefer.;Henrik Falhammar.;Deborah P Merke.;Nicole Reisch.;Kyriakie Sarafoglou.;Gordon B Cutler.;Julia Sturgeon.;Eiry Roberts.;Vivian H Lin.;Jean L Chan.;Robert H Farber.; .
来源: N Engl J Med. 2024年391卷6期504-514页
Adrenal insufficiency in patients with classic 21-hydroxylase deficiency congenital adrenal hyperplasia (CAH) is treated with glucocorticoid replacement therapy. Control of adrenal-derived androgen excess usually requires supraphysiologic glucocorticoid dosing, which predisposes patients to glucocorticoid-related complications. Crinecerfont, an oral corticotropin-releasing factor type 1 receptor antagonist, lowered androstenedione levels in phase 2 trials involving patients with CAH.
73. The Role of Interferon-γ in Autoimmune Polyendocrine Syndrome Type 1.
作者: Vasileios Oikonomou.;Grace Smith.;Gregory M Constantine.;Monica M Schmitt.;Elise M N Ferré.;Julie C Alejo.;Deanna Riley.;Dhaneshwar Kumar.;Lucas Dos Santos Dias.;Joseph Pechacek.;Yannis Hadjiyannis.;Taura Webb.;Bryce A Seifert.;Rajarshi Ghosh.;Magdalena Walkiewicz.;Daniel Martin.;Marine Besnard.;Brendan D Snarr.;Shiva Deljookorani.;Chyi-Chia R Lee.;Tom DiMaggio.;Princess Barber.;Lindsey B Rosen.;Aristine Cheng.;Andre Rastegar.;Adriana A de Jesus.;Jennifer Stoddard.;Hye Sun Kuehn.;Timothy J Break.;Heidi H Kong.;Leslie Castelo-Soccio.;Ben Colton.;Blake M Warner.;David E Kleiner.;Martha M Quezado.;Jeremy L Davis.;Kevin P Fennelly.;Kenneth N Olivier.;Sergio D Rosenzweig.;Anthony F Suffredini.;Mark S Anderson.;Marc Swidergall.;Carole Guillonneau.;Luigi D Notarangelo.;Raphaela Goldbach-Mansky.;Olaf Neth.;Maria Teresa Monserrat-Garcia.;Justo Valverde-Fernandez.;Jose Manuel Lucena.;Ana Lucia Gomez-Gila.;Angela Garcia Rojas.;Mikko R J Seppänen.;Jouko Lohi.;Matti Hero.;Saila Laakso.;Paula Klemetti.;Vanja Lundberg.;Olov Ekwall.;Peter Olbrich.;Karen K Winer.;Behdad Afzali.;Niki M Moutsopoulos.;Steven M Holland.;Theo Heller.;Stefania Pittaluga.;Michail S Lionakis.
来源: N Engl J Med. 2024年390卷20期1873-1884页
Autoimmune polyendocrine syndrome type 1 (APS-1) is a life-threatening, autosomal recessive syndrome caused by autoimmune regulator (AIRE) deficiency. In APS-1, self-reactive T cells escape thymic negative selection, infiltrate organs, and drive autoimmune injury. The effector mechanisms governing T-cell-mediated damage in APS-1 remain poorly understood.
75. Implications of Race Adjustment in Lung-Function Equations.
作者: James A Diao.;Yixuan He.;Rohan Khazanchi.;Max Jordan Nguemeni Tiako.;Jonathan I Witonsky.;Emma Pierson.;Pranav Rajpurkar.;Jennifer R Elhawary.;Luke Melas-Kyriazi.;Albert Yen.;Alicia R Martin.;Sean Levy.;Chirag J Patel.;Maha Farhat.;Luisa N Borrell.;Michael H Cho.;Edwin K Silverman.;Esteban G Burchard.;Arjun K Manrai.
来源: N Engl J Med. 2024年390卷22期2083-2097页
Adjustment for race is discouraged in lung-function testing, but the implications of adopting race-neutral equations have not been comprehensively quantified.
77. Andexanet for Factor Xa Inhibitor-Associated Acute Intracerebral Hemorrhage.
作者: Stuart J Connolly.;Mukul Sharma.;Alexander T Cohen.;Andrew M Demchuk.;Anna Członkowska.;Arne G Lindgren.;Carlos A Molina.;Daniel Bereczki.;Danilo Toni.;David J Seiffge.;David Tanne.;Else Charlotte Sandset.;Georgios Tsivgoulis.;Hanne Christensen.;Jan Beyer-Westendorf.;Jonathan M Coutinho.;Mark Crowther.;Peter Verhamme.;Pierre Amarenco.;Risto O Roine.;Robert Mikulik.;Robin Lemmens.;Roland Veltkamp.;Saskia Middeldorp.;Thompson G Robinson.;Truman John Milling.;Vitor Tedim-Cruz.;Wilfried Lang.;Anders Himmelmann.;Per Ladenvall.;Mikael Knutsson.;Ella Ekholm.;Andrew Law.;Amanda Taylor.;Tetyana Karyakina.;Lizhen Xu.;Kate Tsiplova.;Sven Poli.;Bernd Kallmünzer.;Christoph Gumbinger.;Ashkan Shoamanesh.; .
来源: N Engl J Med. 2024年390卷19期1745-1755页
Patients with acute intracerebral hemorrhage who are receiving factor Xa inhibitors have a risk of hematoma expansion. The effect of andexanet alfa, an agent that reverses the effects of factor Xa inhibitors, on hematoma volume expansion has not been well studied.
79. Recombinant ADAMTS13 for Immune Thrombotic Thrombocytopenic Purpura.
作者: Pavan K Bendapudi.;Brody H Foy.;Sarah B Mueller.;Jun Liu.;Louis M Feingold.;Kristen E Burke.;Wendy Cruz.;Maria Y Chen.;Emily S Lau.;Rachel L Goldberg.;Ishan Tatake.;Shelby C Wilkinson.;Brian J Carney.;James R Stone.;Doyun Park.;Alzira R Avelino.;Sajjad Hassan.;Chester Andrzejewski.;Kristen N Ruby.;Kenneth D Friedman.;Patricia A R Brunker.;Rebecca K Leaf.;John Higgins.;Walter H Dzik.;Jonathan A Stefely.;Robert S Makar.
来源: N Engl J Med. 2024年390卷18期1690-1698页
In patients with immune thrombotic thrombocytopenic purpura (iTTP), autoantibodies against the metalloprotease ADAMTS13 lead to catastrophic microvascular thrombosis. However, the potential benefits of recombinant human ADAMTS13 (rADAMTS13) in patients with iTTP remain unknown. Here, we report the clinical use of rADAMTS13, which resulted in the rapid suppression of disease activity and complete recovery in a critically ill patient whose condition had proved to be refractory to all available treatments. We also show that rADAMTS13 causes immune complex formation, which saturates the autoantibody and may promote its clearance. Our data support the role of rADAMTS13 as a novel adjunctive therapy in patients with iTTP.
80. Gene Editing for CEP290-Associated Retinal Degeneration.
作者: Eric A Pierce.;Tomas S Aleman.;Kanishka T Jayasundera.;Bright S Ashimatey.;Keunpyo Kim.;Alia Rashid.;Michael C Jaskolka.;Rene L Myers.;Byron L Lam.;Steven T Bailey.;Jason I Comander.;Andreas K Lauer.;Albert M Maguire.;Mark E Pennesi.
来源: N Engl J Med. 2024年390卷21期1972-1984页
CEP290-associated inherited retinal degeneration causes severe early-onset vision loss due to pathogenic variants in CEP290. EDIT-101 is a clustered regularly interspaced short palindromic repeats (CRISPR)-CRISPR-associated protein 9 (Cas9) gene-editing complex designed to treat inherited retinal degeneration caused by a specific damaging variant in intron 26 of CEP290 (IVS26 variant).
|